Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery

Journal of International Medical Research

Volumn 42, Issue 3, 2014, Pages 750-764

  Erb, Joachim ^a   Beutlhauser, Torsten ^b   Feldheiser, Aarne ^b   Schuster, Birgit ^b   Treskatsch, Sascha ^b   Grubitzsch, Herko ^b   Spies, Claudia ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

adverse events; cardiac surgery; Levosimendan; organ dysfunction; reduced left ventricular function; Sequential Organ Failure Assessment

Indexed keywords

ADRENALIN; DOBUTAMINE; ENOXIMONE; GLYCERYL TRINITRATE; LEVOSIMENDAN; NORADRENALIN; PLACEBO; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VASOCONSTRICTOR AGENT;

AGED; ANESTHESIA INDUCTION; ARTICLE; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EXTUBATION; FEMALE; FORWARD HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STROKE VOLUME; HEMODIALYSIS; HUMAN; INOTROPISM; INTENSIVE CARE UNIT; INTRAAORTIC BALLOON PUMP; ISCHEMIC CARDIOMYOPATHY; LENGTH OF STAY; MALE; MEAN ARTERIAL PRESSURE; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RICHMOND AGITATION SEDATION SCALE; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS OXYGEN TENSION; VENTRICULAR ASSIST DEVICE; BLOOD PRESSURE; CARDIOMYOPATHIES; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; ENOXIMONE; FEMALE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NOREPINEPHRINE; PROSPECTIVE STUDIES; PYRIDAZINES; STROKE VOLUME; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84904738198     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513516293     Document Type: Article

References (41)

1. Mazzoni M,De Maria R,Bortone F, et al.Long-term outcome of survivors of prolonged intensive care treatment after cardiac surgery.Ann Thorac Surg. 2006;82:2080-2087.
2. Hein OV,Birnbaum J,Wernecke KD, et al.Three-year survival after four major post-cardiac operative complications.Crit Care Med. 2006;34:2729-2737.
3. Moens AL,Claeys MJ,Timmermans JP, et al.Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process.Int J Cardiol. 2005;100:179-190.
4. Westaby S,Balacumaraswami L,Sayeed R.Maximizing survival potential in very high risk cardiac surgery.Heart Fail Clin. 2007;3:159-180.
5. Kersten JR,Montgomery MW,Pagel PS, et al.Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels.Anesth Analg. 2000;90:5-11.
6. Carl M,Alms A,Braun J, et al.S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system.Ger Med Sci. 2010;8:doc12-doc12.
7. Rooke GA,Feigl EO.Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting.Circ Res. 1982;50:273-286.
8. Thackray S,Easthaugh J,Freemantle N, et al.The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis.Eur J Heart Fail. 2002;4:515-529.
9. Takahashi R,Talukder MA,Endoh M.Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium.Eur J Pharmacol. 2000;400:103-112.
10. Banfor PN,Preusser LC,Campbell TJ, et al.Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.Am J Physiol Heart Circ Physiol. 2008;294:H238-H248.
11. Soeding PF,Crack PJ,Wright CE, et al.Levosimendan preserves the contractile responsiveness of hypoxic human myocardium via mitochondrial K(ATP) channel and potential pERK 1/2 activation.Eur J Pharmacol. 2011;655:59-66.
12. Scheiermann P,Beiras-Fernandez A,Mutlak H, et al.The protective effects of levosimendan on ischemia/reperfusion injury and apoptosis.Recent Pat Cardiovasc Drug Discov. 2011;6:20-26.
13. Pollesello P,Papp Z.The cardioprotective effects of levosimendan: Preclinical and clinical evidence.J Cardiovasc Pharmacol. 2007;50:257-263.
14. Caimmi PP,Molinari C,Uberti F, et al.Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide.Eur J Cardiothorac Surg. 2011;39:e59-e67.
15. Markou T,Makridou Z,Galatou E, et al.Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes.Eur J Pharmacol. 2011;667:298-305.
16. De Hert SG,Lorsomradee S,Cromheecke S, et al.The effects of levosimendan in cardiac surgery patients with poor left ventricular function.Anesth Analg. 2007;104:766-773.
17. Tritapepe L,De Santis V,Vitale D, et al.Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery.Br J Anaesth. 2009;102:198-204.
18. Tritapepe L,De Santis V,Vitale D, et al.Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study.Br J Anaesth. 2006;96:694-700.
19. Kox WJ,Spies CDCheck-up anästhesiologie. Berlin, Heidelberg, New York, NY: Springer; 2005:.
20. Calafiore AM,Teodori G,Di Giammarco G, et al.Intermittent antegrade cardioplegia: warm blood vs cold crystalloid. A clinical study.J Cardiovasc Surg. 1994;35:179-184.
21. Ely EW, et al.Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).JAMA. 2003;289:2983-2991.
22. Payen JF, et al.Assessing pain in critically ill sedated patients by using a behavioral pain scale.Crit Care Med. 2001;29:2258-2263.
23. Spies CD,Vincent JCheck-up intensive care and emergency medicine. Berlin, Heidelberg, New York, NY: Springer; 2010:.
24. EuroQol - a new facility for the measurement of health-related quality of life.Health Policy. 1990;16:199-208.
25. Dellinger RP,Vincent JL.The Surviving Sepsis Campaign sepsis change bundles and clinical practice.Crit Care. 2005;9:653-654.
26. McMurray, et al.ESC guidelines for the diagnosis and treament of acute and chronic heart failure.Eur J Heart Fail. 2012;14:803-869.
27. Eriksson HI,Jalonen JR,Heikkinen LO, et al.Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function.Ann Thorac Surg. 2009;87:448-454.
28. Lahtinen P,Pitkänen O,Pölönen P, et al.Levosimendan reduces heart failure after cardiac surgery: A prospective, randomized, placebo-controlled trial.Crit Care Med. 2011;39:2263-2270.
29. Järvela K,Maaranen P,Sisto T, et al.Levosimendan in aortic valve surgery: Cardiac performance and recovery.J Cardiothorac Vasc Anesth. 2008;22:693-698.
30. Levin RL,Degrange MA,Porcile R, et al.The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome.Rev Esp Cardiol. 2008;61:471-479.
31. Toller WG,Stranz C.Levosimendan, a new inotropic and vasodilator agent.Anesthesiology. 2006;104:556-569.
32. Leppikangas H,Järvelä K,Sisto T, et al.Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery.Br J Anaesth. 2011;106:298-304.
33. Giglio M,Dalfino L,Puntillo F, et al.Haemodynamic goal-directed therapy in cardiac and vascular surgery. A systematic review and meta-analysis.Interact Cardiovasc Thorac Surg. 2012;15:878-887.
34. Landoni G,Biondi-Zoccai G,Greco M, et al.Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.Crit Care Med. 2012;40:634-646.
35. Landoni G,Mizzi A,Biondi-Zoccai G, et al.Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials.J Cardiothorac Vasc Anesth. 2010;24:51-57.
36. Al-Shawaf E,Ayed A,Vislocky I, et al.Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery.J Cardiothorac Vasc Anesth. 2006;20:353-357.
37. Burnett AM,Segal N,Salzman JG, et al.Potential negative effects of epinephrine on carotid blood flow and ETCO2 during active compression-decompression CPR utilizing an impedance threshold device.Resuscitation. 2012;83:1021-1024.
38. Ahmed I,House CM,Nelson WB.Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB).J Cardiothorac Surg. 2009;4:24-24.
39. Nielsen DV,Johnsen SP,Madsen M, et al.Variation in use of peroperative inotropic support therapy in cardiac surgery: Time for reflection?.Acta Anaesthesiol Scand. 2011;55:352-358.
40. Nesher N,Alghamdi AA,Singh SK, et al.Troponin after cardiac surgery: A predictor or a phenomenon?.Ann Thorac Surg. 2008;85:1348-1354.
41. Maharaj R,Metaxa V.Levosimendan and mortality after coronary revascularisation: A meta-analysis of randomised controlled trials.Crit Care. 2011;15:R140-R140.